DCOY (Decoy Therapeutics Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by DCOY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Jonathan I Lieber | Director | A | — | — |
| 2026-09-02 | Paul Lammers | Director | A | — | — |
| 2026-09-02 | Peter Klaus Marschel | Chief Business Officer | A | — | — |
| 2026-09-02 | Barbara Louise Hibner | Chief Scientific Officer | A | — | — |
| 2026-09-02 | Patricia G. Gauthier | Director | A | — | — |
| 2026-09-02 | William K. McVicar | Director | A | — | — |
| 2026-09-02 | ARNOLD C HANISH | Director | A | — | — |
| 2026-09-02 | Mark J Rosenblum | Chief Financial Officer | A | — | — |
| 2026-09-02 | Tess Burleson | Director | A | — | — |
| 2026-09-02 | FREDERICK PIERCE II | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 34,844 | — |
| — | Chief Financial Officer | 11,363 | — |
| — | Chief Scientific Officer | 4,216 | — |
| — | Chief Business Officer | 3,900 | — |
| — | Director | 3,418 | — |
| — | Director | 3,002 | — |
| — | Director | 2,002 | — |
| — | Director | 2,002 | — |
| — | Director | 2,001 | — |
| — | Director | 2,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DCOY quote page; the site-wide leaderboard is on the insider transactions hub.